Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Assets (2016 - 2025)

ProQR Therapeutics' Assets history spans 6 years, with the latest figure at $131.3 million for Q4 2025.

  • On a quarterly basis, Assets fell 26.87% to $131.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $131.3 million, a 26.87% decrease, with the full-year FY2025 number at $131.3 million, down 26.87% from a year prior.
  • Assets hit $131.3 million in Q4 2025 for ProQR Therapeutics, down from $179.5 million in the prior quarter.
  • Over the last five years, Assets for PRQR hit a ceiling of $110.5 billion in Q1 2021 and a floor of $122.7 million in Q3 2022.
  • Historically, Assets has averaged $8.1 billion across 5 years, with a median of $177.1 million in 2022.
  • Biggest five-year swings in Assets: soared 103.67% in 2021 and later crashed 99.81% in 2022.
  • Tracing PRQR's Assets over 5 years: stood at $239.8 million in 2021, then fell by 27.1% to $174.8 million in 2022, then fell by 15.12% to $148.4 million in 2023, then grew by 20.98% to $179.5 million in 2024, then fell by 26.87% to $131.3 million in 2025.
  • Business Quant data shows Assets for PRQR at $131.3 million in Q4 2025, $179.5 million in Q4 2024, and $148.4 million in Q4 2023.